GC3110A

BIOLOGICAL2 trials

Sponsors

Green Cross Corporation

Conditions

InfluenzaInfluenza Vaccine

Phase 3

A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children

CompletedNCT02541253

Green Cross CorporationInfluenza

Start: 2015-09-30End: 2016-06-30Updated: 2016-11-07

A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age

Green Cross CorporationInfluenza Vaccine

Start: 2017-09-30End: 2018-08-31Target: 260Updated: 2017-09-18

Related Papers

Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months.

2021-03-162 citations

Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study

Journal of Korean Medical Science2018-01-0114 citations